Search clinical trials for: JMT103

Total 70 results

Amgen Research (Munich) GmbH

Completed

Clinical Study With Blinatumomab in Pediatric and Adolescent Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia

United States, Germany, Austria, Canada, France, Italy, Netherlands
Amgen Research (Munich) GmbH

Completed

Study of the BiTE® Blinatumomab (MT103) in Adult Patients With Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (ALL)

B-ALL

Germany
Amgen Research (Munich) GmbH

Completed

Clinical Study With Blinatumomab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Diffuse Large B-cell Lymphoma

Germany
Amgen Research (Munich) GmbH

Completed

Clinical Study With Blinatumomab in Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)

Acute Lymphoblastic Leukemia

United States, United Kingdom, Germany, Spain, France, Italy
Amgen Research (Munich) GmbH

Completed

Phase II Study of the BiTE® Blinatumomab (MT103) in Patients With Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia (ALL)

Acute Lymphoblastic Leukemia

Germany
Amgen Research (Munich) GmbH

Completed

Safety Study of the Bispecific T-cell Engager Blinatumomab (MT103) in Patients With Relapsed NHL

Non-Hodgkin's Lymphoma, Relapsed

Germany
Shanghai JMT-Bio Inc.
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Unknown

A Clinical Trial to Assess the Efficacy and Safety of JMT103 in Patients With Refractory HCM

Hypercalcemia of Malignancy
Shanghai JMT-Bio Inc.

Not yet recruiting

Efficacy and Safety of JMT103 in the Treatment of Glucocorticoid Induced Osteoporosis

Glucocorticoid Induced Osteoporosis

China
Shanghai JMT-Bio Inc.

Completed

Efficacy and Safety of JMT103 in Patients With Bone Metastases From Solid Tumors

Bone Metastases From Solid Tumors

China
Shaanxi Micot Technology Limited Company
WCCT Global

Completed

MT1013 Clinical TRIAL In Healthy Subject

Healthy Volunteer

United States
Lmito Therapeutics Inc.

Not yet recruiting

LMT503 First-in-human SAD, MAD, and FE Study

Crohn Disease | Colitis, Ulcerative | Inflammatory Bowel Disease

Netherlands
Conjupro Biotherapeutics, Inc.

Suspended

Dose Escalation and Expansion Study of CPO107 for Patients With Advanced CD20-positive Non-Hodgkins Lymphoma

CD20 Positive Non Hodgkin Lymphoma

United States
Shanghai JMT-Bio Inc.

Recruiting

Efficacy and Safety of JMT103 in the Treatment of Postmenopausal Women With Osteoporosis

Postmenopausal Osteoporosis

China
Shanghai JMT-Bio Inc.

Not yet recruiting

A Study to Evaluate the Efficacy and Safety of Narlumosbart (JMT103) in Patients With Giant Cell Tumor of Bone

Giant Cell Tumor of Bone

China
Hugel

Completed

Study to Investigate the Pharmacokinetics, Safety, and Tolerability of BMT101 in Healthy Male Volunteers

Hypertrophic Scar

Korea, Republic of
Shanghai JMT-Bio Inc.

Not yet recruiting

A Study to Assess the Prevention of Bone-related Events in Patients With Bone Metastases From Malignant Solid Tumors Treated With JMT103 Compared to Zoledronic Acid

Imaging Examination Shows at Least One Site With Bone Metastases From Soild Tumors
Hugel

Terminated

the Hypertrophic Scar Prevention of BMT101.

Hypertrophic Scar

Korea, Republic of
Shanghai JMT-Bio Inc.
Quintiles, Inc.; Covance; KingMed Diagnostics

Unknown

Safety, Tolerability and PK/PD of JMT103 in Patients With Bone Metastases From Tumors (JMT103)

Bone Metastases

China
Edward Patz

Active, not recruiting

Phase Ib First in Human Dose Escalation of GT103 in Refractory, Advanced Stage Non-Small Cell Lung Cancer (TOP 1902)

Non-small Cell Lung Cancer

United States
Mthera Pharma Co., Ltd.

Not yet recruiting

A Study to Evaluate the Safety, Tolerability and Efficacy of MT101-5 in Subjects With Early Parkinson's Disease

Parkinson's Disease
Takeda

Completed

Efficacy and Safety of Namilumab (MT203) for Plaque Psoriasis

Plaque Psoriasis

Canada
RenJi Hospital
Shanghai JMT-Bio Inc.

Not yet recruiting

Narlumosbart Compared With Denosumab in Patients With Multiple Myeloma Bone Disease

Multiple Myeloma | Bone Diseases
Blue Note Therapeutics
Healthcare Innovation Technology Lab

Completed

Blue Note Therapeutics Product BNT 103 Usability and User Engagement

Breast Cancer Female

United States
Amgen Research (Munich) GmbH

Completed

Confirmatory Phase II Study of Blinatumomab (MT103) in Patients With Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia (ALL) (BLAST)

B-cell Acute Lymphoblastic Leukemia

Austria, Belgium, France, Germany, Italy, Netherlands, Poland, Romania, Russian Federation, Spain, United Kingdom
American Gene Technologies International Inc.

Completed

Study to Evaluate the Safety of a Gene and Cell Therapy Product in Participants With HIV That is Well-Controlled on Antiretroviral Therapy

HIV

United States
Suzhou BlueHorse Therapeutics Co., Ltd.

Recruiting

A Clinical Study of LM103 Injection in the Treatment of Advanced Solid Tumors

Melanoma | Non Small Cell Lung Cancer | Cervical Carcinoma

China
Peking University

Recruiting

JMT101 Combined With Afatinib in Patients With Advanced Esophageal Squamous Cell Carcinoma After Standard Therapy

Esophageal Squamous Carcinoma

China
Vyne Therapeutics Inc.

Completed

A Study to Evaluate the Long-Term Safety of Topical Administration of FMX103 in the Treatment of Moderate to Severe Papulopustular Rosacea

Papulopustular Rosacea

United States
GeneMedicine Co., Ltd.

Recruiting

GM103 Intratumoral Injection in Patients With Locally Advanced, Unresectable, Refractory and/or Metastatic Solid Tumors

Renal Cell Carcinoma | Cervical Cancer | Breast Cancer | Head and Neck Cancer | Colorectal Cancer | Malignant Melanoma

Korea, Republic of
Takeda

Completed

Single-Dose Study of MT203

Healthy Volunteers

Japan
Mthera Pharma Co., Ltd.
Amarex Clinical Research

Completed

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics Profile of MT101-5 in Healthy Volunteers

Parkinson's Disease

United States
Institute of Hematology and Blood Transfusion,...
CZECRIN - Czech Clinical Research Infrastructure Network

Completed

Blinatumomab Followed by High-dose Chemotherapy for Ph-negative Acute Lymphoblastic Leukemia (ALL) (Blina-CELL)

Newly Diagnosed | Lymphoblastic Leukemia, Acute, Adult | Ph Negative ALL

Czechia
Shanghai JMT-Bio Inc.

Not yet recruiting

Efficacy and Safety of JMT101 Combined Wth Docetaxel / HB1801 in Patients With Squamous Cell Non-Small Cell Lung Cancer

Squamous Cell Non-small Cell Lung Cancer
Shanghai JMT-Bio Inc.
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Not yet recruiting

Efficacy and Safety of JMT101 Combined With Osimertinib in Patients With Non-Small Cell Lung Cancer

Locally Advanced or Metastatic Non-Small Cell Lung Cancer | EGFR Exon20 Insertion Mutations
Suzhou BlueHorse Therapeutics Co., Ltd.

Not yet recruiting

A Clinical Study on LM103 Injection for the Treatment of Advanced Solid Tumors

Solid Tumor
Shanghai JMT-Bio Inc.

Not yet recruiting

A Study of JMT101 in Patients With Metastatic Colorectal Cancer

Metastatic Colorectal Cancer (mCRC)
Amgen

Completed

Efficacy and Safety of the BiTE Antibody Blinatumomab in Chinese Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)

Acute Lymphoblastic Leukemia

China
Suzhou BlueHorse Therapeutics Co., Ltd.

Not yet recruiting

A Clinical Study on TILs for the Treatment of Advanced Solid Tumors

Solid Tumor
Suzhou BlueHorse Therapeutics Co., Ltd.

Recruiting

A Clinical Study on LM103 for the Treatment of Advanced Solid Tumors

Solid Tumor

China
Shanghai JMT-Bio Inc.
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Unknown

Efficacy and Safety of JMT101 Combined With Afatinib (or Osimertinib) in Patients With Non-Small Cell Lung Cancer

Locally Advanced or Metastatic Non-Small Cell Lung Cancer

China
Amgen

Terminated

Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)

Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia

United States, France, Italy, Belgium, Canada, Mexico, Germany, Korea, Republic of, United Kingdom, Taiwan, Australia, Spain, Austria, Israel, Czechia, Greece, Russian Federation, Poland, Turkey, Bulgaria, Ireland
Amgen

No longer available

Expanded Access Protocol - Blinatumomab in Pediatric & Adolescent Subjects With Relapsed/Refractory B-precursor ALL (RIALTO)

Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia

United States, Italy, Germany, Austria, France, Switzerland, United Kingdom
Vyne Therapeutics Inc.
Premier Research Group plc

Completed

A Study (Study 1) to Evaluate the Safety and Efficacy of FMX103 1.5% Topical Minocycline Foam in the Treatment of Facial Papulopustular Rosacea

Facial Papulopustular Rosacea

United States
Vyne Therapeutics Inc.
Premier Research Group plc

Completed

A Study (Study 2) to Evaluate the Safety and Efficacy of FMX103 1.5% Topical Minocycline Foam in the Treatment of Facial Papulopustular Rosacea

Facial Papulopustular Rosacea

United States
Takeda

Completed

A Trial to Evaluate the Safety and Tolerability of Namilumab (MT203) in Patients With Mild to Moderate Rheumatoid Arthritis (PRIORA)

Rheumatoid Arthritis

Bulgaria, Netherlands
National Cancer Institute (NCI)

Recruiting

Inotuzumab Ozogamicin and Blinatumomab in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

Recurrent B Acute Lymphoblastic Leukemia | Refractory B Acute Lymphoblastic Leukemia | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative

United States
National Cancer Institute (NCI)

Active, not recruiting

Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma

Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell... and other conditions

United States
Amgen
Merck Sharp & Dohme LLC

Completed

Study Investigating the Safety and Efficacy of Blinatumomab in Combination With Pembrolizumab in Adults With Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL) (HARBOUR)

Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL)

United States, Germany, Spain, Australia, Netherlands, France
Jeffrey Clarke
Merck Sharp & Dohme LLC; Grid Therapeutics

Suspended

Study of GT103 in Combination With Pembrolizumab in Refractory, Metastatic Non-Small Cell Lung Cancer

Non Small Cell Lung Cancer | Metastatic NSCLC | Recurrent Non Small Cell Lung Cancer

United States
Shanghai JMT-Bio Inc.

Not yet recruiting

JMT101 in Combination With Osimertinib, Versus Cisplatin-pemetrexed in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Exon 20ins Mutations

Local Advanced or Metastatic NSCLC

Search clinical trials for: JMT103

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Georgia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations